Sherene Loi, MD, PhD, on Early-Stage Breast Cancer: Weighing the Prognostic Value of ctDNA Detection
2024 ASCO Annual Meeting
Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre, discusses a circulating tumor DNA (ctDNA) analysis from a cohort of patients with early-stage breast cancer who were enrolled in the monarchE trial. This large cohort was studied to look at the usefulness of a personalized tumor-informed assay for ctDNA detection in early stage high-risk patients (LBA507).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The monarchE study was a trial which was looking specifically a high-risk node-positive estrogen receptor positive early-stage breast cancer patients. We know that these patients have an extremely high risk of recurrence, particularly those that have four or more nodes or larger tumors with one to three positive nodes or high grade. The monarchE study showed the benefit of two years of adjuvant abemaciclib when added to endocrine therapy. In this particular study, we looked at 910 patients from the monarchE study. These patients were cross-treatment arms, and this group was enriched for invasive disease events. This is because we wanted to look at the sensitivity of the assay. The assay's tumor-informed, which means whole exome sequencing was performed on the primary tumor, and then each assay was designed specifically for the individual patient using that information. Patients had blood samples taken at baseline, so prior to treatment, or at three, six, or at the end of 24 months of treatment.
What we found in these 910 patients was that the detection of ctDNA positivity at baseline occurred in about 8% of patients. This is a very low frequency of patients had positive ctDNA by this assay compared to the 27% of patients who had events that was enriched in this study. This was despite a high-risk population. What we did find, however, that serial sampling was very informative. Some patients that were undetectable at baseline became detectable. This was a further 10% of patients, so around 17% of patients of the 27% of patients who had an event were picked up by this assay.
Of most interest was the patients that were negative or undetectable at baseline that became positive. We know that they did poorly actually. Most of these patients recurred, 100% of patients recurred. There were patients that were positive at baseline that remained positive. Those patients also did poorly, 100% rates. Of most interest to me were the patients who were positive at baseline, but then became undetectable using serial sampling. These patients had a better outcome than those patients who remained positive by the ctDNA. This suggests that the treatment was having an effect on the disease, perhaps curing some patients. This suggests that clearance of ctDNA may be a useful surrogate endpoint for evaluation of future therapies in the future or in future clinical trials. Our data also suggests that patients who are positive for ctDNA at baseline and remain positive have very aggressive disease and are resistant to treatment and in the future will need some sort of rethink or different types of therapy quite early on.
Related Videos
The ASCO Post Staff
Eva M. Ciruelos, MD, PhD, of Spain’s Hospital 12 de Octubre and the Instituto de Investigación Sanitaria Hospital 12 de Octubre, discusses phase II data showing that the combination of palbociclib, trastuzumab, and endocrine therapy improved progression-free survival in patients with previously treated PAM50 luminal A or B, HER2-positive advanced breast cancer, as compared with treatment of physicians’ choice (Abstract 1008).
The ASCO Post Staff
Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).
The ASCO Post Staff
Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).
The ASCO Post Staff
Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, discusses recent findings from the CARTITUDE-4 trial showing that, in patients with lenalidomide-refractory functional high-risk multiple myeloma after one prior line of treatment, ciltacabtagene autoleucel improved outcomes vs the standard of care (Abstract 7504).
The ASCO Post Staff
Don S. Dizon, MD, of Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, discusses final phase II results of the BrUOG 354 trial showing that, for patients with ovarian and other extrarenal clear cell cancers, nivolumab and ipilimumab warrant further evaluation against standard treatment, given the historically chemotherapy-resistant nature of the disease (LBA5500).